Moderna has already said it won& #39;t enforce its patents. That& #39;s not the barrier to duplicating its vaccine. https://twitter.com/ElsTorreele/status/1386414933672292352">https://twitter.com/ElsTorree...

There& #39;s a lot of fuzziness in the way people write about the question of what& #39;s actually needed for developing countries to be able to produce mRNA vaccines on their own. People mush "IP rights" and "technology transfer" together when they& #39;re 2 v. different things.

Making mRNA vaccines is not like making a generic version of a conventional drug: it& #39;s a new, much more complicated and fragile process, dependent on a great deal of tacit knowledge (and special materials, etc.) https://blogs.sciencemag.org/pipeline/archives/2021/02/02/myths-of-vaccine-manufacturing">https://blogs.sciencemag.org/pipeline/...

That& #39;s why the most obvious solution is for the US, Europe, and Japan to pay Pfizer and Moderna to license their technology and transfer their knowledge to developing-country manufacturers.